Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
485 participants
OBSERVATIONAL
2023-03-15
2025-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy of Voice Treatment for Parkinson's Disease
NCT00123084
A Novel Measurement Concept to Objectively Quantify Severity of Vocal and Speech Related Symptoms Associated With Parkinson's Disease
NCT05421832
Speech, Linguistic and Acoustic Markers in Parkinson's Disease
NCT04273672
Voice Treatment for Parkinson's Disease
NCT03700684
Intelligibility Assessment for Parkinson's Disease
NCT04829006
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
(600 samples/person x 400 persons/etiology x 5 etiologies = 1,200,000 samples)
Our schedule of research procedures is:
1. February or March-August 2023: data collection of speech samples from 400 people with Parkinson's.
2. August 2023-August 2025: data collection of speech samples from 1,600 people with ALS, CP, DS, and Stroke.
Data collection of speech samples in Year 1 will be a collaboration of the University of Illinois and of mentors from Lee Silverman Voice Therapy (LSVT) Global. Potential participants will be screened both with a questionnaire and by providing a short set of "quality control" speech samples. If the participant does not pass screening, they will be thanked for their interest. Otherwise, the participant is eligible for the study and can do the informed consent process and then engage in contributing speech samples.
Participants can do as many recordings as they wish at whatever time of day is convenient for them. Participants will be able to login to the system at any time, 24/7.
In Year 2, this procedure will be performed with patients from other etiologies with additional advocacy organizations as partners.
Participants who are unable to read text from the computer screen will be offered the opportunity to record speech using a verbal-repetition protocol. In order to participate in the verbal repetition protocol, a participant must be accompanied by a caregiver who is also willing to be recorded. If a participant agrees to this protocol, then the caregiver will read each prompt to the participant. The participant will then repeat the words spoken by the caregiver, or respond to any question asked by the caregiver.
Participants also have the option to provide additional data about themselves, such as their age, race and ethnicity, and the year of their diagnosis. These "metadata tags" are completely optional but are helpful for analysis.
The collected speech samples will be stored securely in a custom database built by the UIUC Beckman Institute. All samples are stored with a unique participant ID code. All samples are annotated by our UIUC research team with technical information about the acoustic waveform and other information.
The entire database of speech samples will be shared with our coalition partners (Amazon, Apple, Google, Meta, and Microsoft), and, after all data collection is complete, with other universities and companies who are willing to sign our data use agreement. Each partner has signed a data use agreement with UIUC that allows these deidentified data to be used for improvements in speech recognition technology and assures the privacy of participants and confidentiality of data.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
ECOLOGIC_OR_COMMUNITY
CROSS_SECTIONAL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Self-reported diagnosis of Parkinson's Disease, ALS, CP, DS, or Stroke
* Reads and speaks English in the form of complete sentences
* Has a valid email address
* Ability to access web browser to participate in study
Exclusion Criteria
* If quality control screening of initial speech samples "fails" because of poor data quality (e.g., poor quality recording environment, or person's speech is "too typical" and not sufficiently interesting to continue collecting)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
LSVT Global
UNKNOWN
Amazon, Inc.
INDUSTRY
Apple Inc.
INDUSTRY
Google LLC.
INDUSTRY
Meta Platforms, Inc.
UNKNOWN
Microsoft Corporation
INDUSTRY
University of Illinois at Urbana-Champaign
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mark A Hasegawa-Johnson, Ph.D.
Role: PRINCIPAL_INVESTIGATOR
University of Illinois at Urbana-Champaign
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
LSVT Global
Denver, Colorado, United States
University of Illinois at Urbana-Champaign
Urbana, Illinois, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol, Statistical Analysis Plan, and Informed Consent Form
Related Links
Access external resources that provide additional context or updates about the study.
Project information and contact information
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
23183
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.